Skip to content

News · CDMO

Developers pick AGC Biologics Yokohama for cell therapy

· Sources: 1 · Translated from the Japanese edition

Photo: Yucel M / Unsplash

AGC Biologics said on November 17, 2026 that three biopharma developers, including the Institute of Science Tokyo, have chosen its Yokohama site for cell therapy services. The site offers process transfer and manufacturing for non-clinical work and clinical trials. One of the new projects is a customer program moving to Yokohama from the company's Milan site.

What the Yokohama site takes on, and for which cell types

For a developer working in Japan, the first question is what can be placed there. AGC Biologics lists process transfer and manufacturing services for non-clinical and clinical work, and names five core technologies: induced pluripotent stem cells, mesenchymal stem cells, hematopoietic stem cells, exosomes and CAR-T.

The site is recent. AGC established cell therapy services in Yokohama in July 2025, and says it brought together thirty years of expertise at its Milan site and the AGC Group's century-plus manufacturing base in Japan.

A customer program transfers from Milan to Yokohama

One project is the transfer of a customer program from Milan, where AGC will carry out development and manufacturing in Yokohama from now on. Milan is the company's Cell and Gene Center of Excellence. Development and manufacturing by the Cell and Gene Technologies Division has led to 18 commercial approvals for customers and their products, the company says.

Moving a process between sites is where the work sits. Equipment, raw materials and scale all differ, so the question is which of those differences reach the product, and how equivalence will be shown. Tadashi Murano, President of AGC Life Science Company, said the company combines technologies developed across its global network with AGC's materials expertise to support customers from early development through commercialization.

The Institute of Science Tokyo program is process and analytical development

The academic program is a third-party virus-specific T cell therapy for treatment-resistant adenovirus infections after hematopoietic cell transplantation, supported by the Japan Agency for Medical Research and Development under its research program for intractable diseases. Yokohama provides process development and analytical method development, which AGC describes as intended to make future clinical and manufacturing implementation easier.

Third-party means allogeneic: the T cells are prepared in advance from donors. Donor selection and the design of the cell bank then become premises of the process rather than downstream decisions.

What to settle before placing work in Japan

The first line to draw is scope. Decide how much of process development, analytical development, non-clinical manufacturing and clinical trial manufacturing goes to one partner, and where it comes back in-house. If the partner develops the analytical methods, settle in the contract who sets the specifications, who owns the method, and who is responsible for transferring it to another laboratory later.

For a program that moves between sites, line up the comparison before the transfer, not after. Viability and yield, surface markers, potency and impurities all need to be measurable against the same criteria on both sides.

Making clinical trial material in Japan brings the site's licence into the picture: which category it holds as a manufacturing site for regenerative medical products, and which steps fall inside it. The same stage is when raw material specifications, record formats and test items get revisited for manufacturing under GCTP, Japan's standard for regenerative medical products. Capacity is the last item, and the one most often left late: when a suite is free, and how changeover between products sharing it is handled.

Sources

  1. AGC Biologics Welcomes Multiple Cell Therapy Projects to New Yokohama Site. AGC Biologics, Nov 2026.

Read this story in Japanese